Drug Trial Radar · NCT01729754
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)
Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,090
Actual
Start
Feb 5, 2013
Primary completion
Sep 28, 2015
Study completion Oct 26, 2021
Sponsor
- Lead sponsor
- Sun Pharmaceutical Industries LimitedIndustry
- Sponsor type
- Industry
- First posted
- Nov 20, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to evaluate the efficacy and safety/tolerability of tildrakizumab (SCH 900222/MK-3222) in a population of participants with moderate-to-severe plaque psoriasis. The primary hypotheses of the study are that tildrakizumab is superior to placebo in the treatment of moderate-to-severe chronic plaque psoriasis as measured by the proportion of participants achieving \>= Psoriasis Area Sensitivity Index of 75% (PASI-75) response and the proportion of participants with a Physician's Global Assessment (PGA) score of "clear" or "minimal" with at least a 2 grade reduction from baseline at Week 12.
Conditions
- Plaque Psoriasis
Interventions
Tildrakizumab 200 mgDrug
Tildrakizumab 200 mg administered SC. Each pre-filled syringe (PFS) or autoinjector (AI) contains 1 mL of solution, tildrakizumab 100 mg/mL.
Tildrakizumab 100 mgDrug
Tildrakizumab 100 mg administered SC. Each PFS or AI contains 1 mL of solution, tildrakizumab 100 mg/mL.
Tildrakizumab PlaceboDrug
Matching placebo to tildrakizumab administered SC
Etanercept PlaceboDrug
Matching placebo to etanercept administered SC
Etanercept 50 mgDrug
Etanercept 50 mg administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving a Psoriasis Area Sensitivity Index 75% (PASI-75) Response at Week 12 (Part 1)Time frame: Week 12
- Percentage of Participants With a Physician's Global Assessment (PGA) Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 12 (Part 1)Time frame: Week 12
- Percentage of Participants Experiencing an Adverse Event (AE) Up to Week 12 (Part 1)Time frame: Up to Week 12
- Percentage of Participants Discontinuing Study Treatment Due to an AE Up to Week 12 (Part 1)Time frame: Up to Week 12
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.